News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
43% Relative Improvement Versus Control Group In Hard-To-Heal Venous Leg Ulcers Obtained With XCELLentis’ LyphoDerm(TM)
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
XCELLentis, a wholly owned subsidiary of Innogenetics, today announced the top line results of its open-label phase 2 clinical trial with LyphoDerm™ for the treatment of hard-to-heal venous leg ulcers.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
MORE ON THIS TOPIC
Insights
From Grants to Family Offices: Building a Unified Financing Strategy in Biotech
March 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
March 4, 2026
·
1 min read
·
Heather McKenzie
Insights
Rethinking Biotech’s Valley of Death as Federal Grants and Family Offices Step In
March 4, 2026
·
3 min read
·
Jennifer Smith-Parker
IN PARTNERSHIP WITH MEDSIR
Webinar: The Future is Collaborative: Transforming Clinical Trials
March 3, 2026
·
1 min read
·
BioSpace Insights
